Literature DB >> 25893263

Role of age in association between gastric cancer and Helicobacter pylori eradication in cases with intestinal metaplasia and dysplasia.

Ali Kabir1,2,3.   

Abstract

Entities:  

Keywords:  Age; Gastric dysplasia; Intestinal metaplasia

Mesh:

Substances:

Year:  2015        PMID: 25893263     DOI: 10.1007/s10120-015-0498-8

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN: 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  2 in total

1.  Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis.

Authors:  Hai-Ning Chen; Zhu Wang; Xiao Li; Zong-Guang Zhou
Journal:  Gastric Cancer       Date:  2015-01-22       Impact factor: 7.370

Review 2.  Eradication of gastric cancer is now both possible and practical.

Authors:  Akiko Shiotani; Putao Cen; David Y Graham
Journal:  Semin Cancer Biol       Date:  2013-07-19       Impact factor: 15.707

  2 in total
  3 in total

1.  Surveillance strategy according to age after endoscopic resection of early gastric cancer.

Authors:  Hyo-Joon Yang; Sang Gyun Kim; Joo Hyun Lim; Ji Min Choi; Sooyeon Oh; Jae Yong Park; Seung Jun Han; Jung Kim; Hyunsoo Chung; Hyun Chae Jung
Journal:  Surg Endosc       Date:  2017-07-21       Impact factor: 4.584

2.  Impacts of H. pylori mixed-infection and heteroresistance on clinical outcomes.

Authors:  Masoud Alebouyeh; Abbas Yadegar; Nastaran Farzi; Marzyieh Miri; Homayoon Zojaji; Somayeh Gharibi; Zeinab Fazeli; Naser Ebrahimi Daryani; Hamid Asadzadeh Aghdaei; Mohammad Reza Zali
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2015

3.  The Single-Nucleotide Polymorphism of miR-27a rs895819 and the Expression of miR-27a in Helicobacter pylori-Related Diseases and the Correlation with the Traditional Chinese Medicine Syndrome.

Authors:  Ling Zhang; Meng-Xin Huang; Dan-Yan Li; Yun-Zhan Zhang; Shao-Yang Lan; Qi Luo; Yun-Kai Dai; Yun-Bo Wu; Jin-Tong Ye; Wei-Jing Chen; Ru-Liu Li; Ling Hu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-15       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.